DecoDerma among the most interesting global rare disease drug development breakthroughs according to pharmaceutical industry
DecoDerma participated in the Global Challenges campaign on rare diseases organized by the IN-PART. Based on the interest shown by the R&D teams of global pharmaceutical companies DecoDerma gathered interest among the most interesting global rare disease drug development breakthroughs (IN-PART).
The DecoDerma team is led by Professor & Chief Surgeon Tero Järvinen (M.D., Ph.D.), Tampere University (Finland). The team is developing a potentially life-saving drug for devastating rare pediatric skin disease, epidermolysis bullosa. Their molecule is a recombinant, multi-functional fusion protein that has both a targeting peptide (tCRK peptide) for a delivery to normal skin and skin wounds and Decorin (DCN) anti-inflammatory and anti-fibrotic protein as an active therapeutic component. The team has demonstrated the best-in-class position in the lethal, pre-clinical disease model of EB.
DecoDerma has carried out proof-of-concept studies successfully, already received the orphan drug designation (ODD) for their molecule from both the EMA and the FDA. DecoDerma was selected as one of the most promising startup companies in Scandinavia by both the Nordic Innovation Fair (NIF) and the Nordic Life Science days (NLSD) in 2022. SPARK Stanford and SPARK Global startup incubator programs selected DecoDerma among the best 10 global academic biotech startup companies in 2023. DecoDerma is currently raising capital for moving the molecule to clinical trials in EB patients to address the unmet medical need in one of the most devastating diseases in mankind.
More info can be found on our project website DecoDerma. Concerning the Global Challenges in rare diseases by IN-PART, further information can be obtained from info [at] in-part.co.uk .